Biopharma Quality & QA Executive Search.
Retained, partner-led search for the Quality leaders who carry a company’s regulatory and manufacturing risk: Chief Quality Officers, VPs of Quality, Heads of QA and QC, and quality systems leaders for biotech and pharma sponsors and CDMOs. Diagnostic-first, calibrated to your stage and your GMP exposure, not a résumé keyword match.
Quality is the last function to get a seat, and the first to get blamed.
Source: Phase 3 Search analysis of the FDA’s full published CRL archive, July 2026 (The Complete Response Letter Report; the 74% reconciliation is in the methodology). Corroborated by Jefferies (Andrew Tsai) and Mizuho (Graig Suvannavejh), May 2026.
Hiring that person is a governance decision, not an HR task. A Head of Quality owns the systems that make quality repeatable and defensible to a regulator: the GxP framework, inspection readiness, supplier and CDMO oversight, and data integrity. Get the system right and the audits are quiet. Get it wrong and it surfaces at the worst possible moment, in a pre-approval inspection or a warning letter. This is the Durable mandate from our CTO Mandate Framework: quality systems that survive inspections, shortages, and turnover.
The Quality leadership ladder.
Four searches that share a title, and little else.
The board seat
We look for leaders who have taken a quality system through a pre-approval inspection and a commercial launch, who can brief an audit committee without a slide deck, and who have said no to a CEO over a batch and kept the job. The pool is small and mostly not looking; the search is run through the network, not the database.
The system builder
The hire that decides whether quality is a function or a culture. We calibrate for modality (a cell therapy VP Quality and a small-molecule VP Quality are different jobs), for manufacturing model (internal plant versus CDMO network) and for the inspection the company will face next, then assess against the Durable mandate.
The disposition owner
Batch release, deviations, CAPA and change control are where quality either holds or quietly fails. We look for Heads of QA who have run disposition under pressure at a CDMO or a commercial site, and who can write a quality agreement a partner will actually follow.
The analytical seat
Method validation, stability programs and laboratory data integrity sit with QC, and FDA Form 483 observations increasingly cite the lab. We search QC leadership as its own market: analytical scientists who became leaders, not QA generalists with a QC line in the org chart.
The right Quality leader for your stage.
Quality is not one hire. The profile changes as the risk changes. A diagnostic you can run on your own company.
QA foundations
The first quality system and the GMP posture that lets you make clinical-grade material a regulator will accept.
GxP & CDMO oversight
GCP/GMP quality across a growing program, and the oversight muscle to manage quality at a contract site you do not control.
The CQO decision
Inspection readiness becomes board-level risk. The inflection where most companies first need a Chief Quality Officer.
Quality at scale
Systems maturity: quality that holds across volume, sites, shortages, and turnover, not by heroics.
We assess against the mandate, not the résumé.
Every Quality search begins with a diagnostic across the stakeholder base: what the business actually is, where it needs to go, and where the board and management disagree about what the role requires. We build a function-specific maturity framework calibrated to your stage, and assess every candidate against the Durable mandate: can this leader build a quality system that survives an inspection, a supply shock, and the departure of the person who built it. Retained, partner-led, and diagnostic-first, through the Quality, CMC and Technical Operations networks we have worked for 13 years across sponsors and CDMOs.
Biopharma Quality search, in plain terms.
When does a biotech need a Chief Quality Officer?
Typically at the pre-approval inflection, when inspection readiness and commercial quality systems become board-level risk. Before that, a VP or Head of Quality usually carries the function. The trigger is the pivotal campaign and the pre-approval inspection, not headcount.
Who places VP of Quality and Head of Quality leaders at biotech companies?
Specialist life-sciences search firms with a dedicated Quality practice. Phase 3 Search places Chief Quality Officers, VPs of Quality, Heads of QA and QC, and Quality Systems leaders for biotech and pharma sponsors and for CDMOs, through a retained, partner-led search that begins with a diagnostic of the quality system the company actually needs at its stage.
What is the difference between QA and QC leadership?
QC owns testing, confirming material meets specification: release, stability and the analytical data behind both. QA owns the system: the GxP processes, documentation and controls that make quality repeatable and defensible to a regulator. Senior Quality leaders are hired primarily for the QA-and-systems judgment; a VP Quality Control is a distinct, more analytical seat.
Do you place Quality leaders into CDMOs as well as sponsors?
Yes. Site quality heads, VPs of Quality and quality systems leaders for contract development and manufacturing organisations are a core part of the practice. CDMO quality leadership is a different job from sponsor quality: more clients, more inspections and a commercial relationship to protect, and we calibrate for it.
How long does a Quality executive search take?
A typical engagement is completed within 90 days of the brief. Timelines vary with role seniority, scope and company stage; case studies are available on request.
How does Phase 3 assess a Head of Quality?
Against the Durable mandate from our CTO Mandate Framework: whether the leader can build quality systems that survive inspections, shortages and turnover, not whether their résumé lists the right acronyms. Every candidate is scored on the same structured rubric, and the read-back to the board says where we think the quality system is actually exposed.
Quality leadership placed where the inspection is decided.
Placements and partnerships across Alnylam, BioMarin, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, KBI Biopharma, Nitto Avecia, Spark Therapeutics and Vertex, spanning sponsor quality organisations and CDMO site quality. Companies we have placed into have since exited for an aggregate of over $7.3Bn, and Phase 3-placed leaders have helped move 125+ assets toward launch.
“The best search experience I have had in my whole career. The successful candidate has been exceptional.”Tim Maines · CTO Quality, Alnylam Pharmaceuticals
Quality and the filing, in depth.
What the FDA’s published letters say about manufacturing and quality, and the mandate a Quality leader carries.
Updated October 2026 · Author: Alex Cooke, Founder & CEO
Run the diagnostic on your next hire.
Thirty minutes. A structured read on the role. We tell you whether search is the right product, whether the brief reflects the company you are actually inheriting, and whether the leadership architecture sits where it needs to be for your next capital event.